Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China

This article was originally published in PharmAsia News

Executive Summary

SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
Advertisement

Related Content

Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs
Korea’s SK Chemicals Looks To Sell First Generic Patch Of Novartis’ Exelon In Europe
Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
The Rise Of The Chinese CRO: New Models For An Emerging Player
The Rise Of The Chinese CRO: New Models For An Emerging Player
Advertisement
UsernamePublicRestriction

Register

SC076489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel